Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

NCT01823198 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01823198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
June 11, 2013
Completion date
May 10, 2022
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute erythroid leukemia, acute megakaryoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, acute myeloid leukemia in remission, blast phase chronic myelogenous leukemia, bcr-abl1 positive, blasts under 20 percent of bone marrow nucleated cells, blasts under 20 percent of peripheral blood white cells, chronic myelomonocytic leukemia, high risk myelodysplastic syndrome, myelodysplastic syndrome, recurrent chronic myelogenous leukemia, bcr-abl1 positive, therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndrome